HypertensionPhase 1NCT06773975
The Effect of an Oral Nutritional Supplement on the Nutritional and Health Outcomes of the Elderly
A Phase 1 study testing Oral nutritional supplementation in people with Hypertension and Hand Grip Strength, run by University of Ghana at 1 site in Ghana.
Trial summary
I am conducting this research to find out if a peanut based food that is ready to use would improve the nutritional and health outcomes of the elderly when they consume it daily for 12 weeks. Eligible participants will be assigned randomly to any of these 2 groups. 1. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hypertension, Hand Grip Strength, Body Weight
- What is being tested?
- Oral nutritional supplementation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 81 participants
- Where
- 1 siteGhana
- Study dates
- 24 Nov 2025to 1 Apr 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Elderly individuals aged 60 years and above
- Consent to participate
Who cannot join
- Peanut allergy
- Millet allergy
- Sesame seeds allergy
- The use of oral nutritional supplement
- Sickle cell disease
- End stage and terminal illness (cancer, stroke, liver disease, dialysis)
Show all 11Show fewer
- Clinical depression
- Speech impairment
- Hearing impairment
- Visual impairment
- Cognitive impairment Screening/for cognitive impairment; the Abbreviated Mental Test Score by HODKINSON (1972) was adapted for use.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A 12-week Pilot Randomized Controlled Trial of an Oral Nutritional Supplement in Improving the Nutritional and Health Outcomes of the Elderly in Peri Urban Communities of the La Nkwantanang Madina Municipality in the Greater Accra Region
I am conducting this research to find out if a peanut based food that is ready to use would improve the nutritional and health outcomes of the elderly when they consume it daily for 12 weeks. Eligible participants will be assigned randomly to any of these 2 groups.
- To consume the food once a day in between meals in addition to their usual food for 12 weeks (3 months) or
- A control group that will not be given the food. Measurements such as weight, blood pressure and the hand grip strength will be taken at the certain points of the study. A sterile needle will be used to draw about 5 ml of venous blood (from the arm) at the beginning of the study and after 12 weeks. Analyses would be carried out on the blood to know if the food has made an impact on serum albumin, ferritin, haemoglobin and cholesterol. If the findings of the study are favourable, it would provide insights for a larger randomized controlled trial that could establish the efficacy of a locally produced peanut based food for the feeding of the elderly.
Read the detailed description
Study design A hybrid study comprising of a cross sequential study and a randomized controlled trial.
Study area The study locations are the following five peri urban communities out of the ten peri urban communities in the La Nkwantanang Madina Municipality (LANMA) of the Greater Accra Region in Ghana; Ayi Mensah, Kweiman, Danfa, Adoteiman and Otinibi. These have been conveniently selected because they are a continuous stretch of five communities in the order listed above to reduce the cost of transportation of data collectors and logistics, distribution of the intervention and data collection based on funds available for the project.
Sample size Assumptions: A Cohen's medium effect size of 0.3, a statistical power of 80% at a 5% level of significance, G-power 3.9.1.7 software generated a sample size of 90 participants per treatment group. Accounting for attrition rate + loss to follow up of 10% = 99 participants * 2 treatment groups
= A total sample size of 198 elderly individuals. This has been rounded off to 200 participants. The census to recruit the 200 eligible participants has been completed as of December 13, 2024.
A cross-sectional survey to identify the relationship between usual dietary intake, handgrip strength and blood pressure has been conducted for the 200 participants. Eighty of the participants will be randomly selected as participants for a 12 week randomized control trial.
Assumptions (80 participants): A Cohen's medium effect size of 0.25, a statistical power of 90% at a 5% level of significance, GPower 3.1.9.4 generated a sample size of 36 participants per treatment group. Accounting for attrition rate and a loss to follow up of 10% = 40 participants * 2 treatment groups. A total sample size of 80 elderly individuals.
Data collection for the randomized control trial An interviewer administered questionnaire will be used to obtain the following information at different points of assessments
Baseline data collection Sociodemographic characteristics and medical history such as age, sex, highest level of education, marital status, ethnicity and use of iron supplements, anti-hypertensive drugs and cholesterol lowering drugs will be collected.
Baseline, midline (6 weeks) and endline (12 weeks) A multiple pass quantitative 24-hour dietary recall to obtain information on dietary intake. Household measures and food models will be used to estimate portion sizes. The Physical Activity Scale for the Elderly (PASE) by Washburn et al. (1993) will be used to measure level of physical activity. Body weight, hand grip strength, systolic and diastolic blood pressure will be measured.
Weekly All participants will receive nutrition education at baseline and weekly thereafter. Information on adherence will be collected by evidence of pouches of previous week's ration to calculate percentage of quantity consumed. The 24-hour dietary recall will also be used to track adherence. Information on morbidity on the use of oral nutritional supplements will be collected using the questionnaire for gastrointestinal problems adapted from Pereira et al. (2014).
Baseline and 12 weeks A qualified phlebotomist will take a 5ml venous blood for analyses of the following: serum albumin, serum ferritin, serum cholesterol and haemoglobin
The intervention A 7-day ration of the oral nutritional supplement will be distributed to the intervention arm once a week. A day's serving of 330 ml is to be consumed in between meals. After endline data collection, the control arm will be given a ration of the oral nutritional supplement that will be enough for one month.
Statistical analyses
- To investigate the effect of sociodemographic characteristics, dietary intake and level of physical activity on the outcome measures, binary logistic regression for categorical variables, multinomial or ordinal logistics regression for multiple variables and linear regression for continuous variables
- To determine the efficacy of the oral nutritional supplement on outcome measures within the same treatment arm, repeated measures ANOVA and paired-sample t-test will be used
- To determine the differences in outcomes between the treatment groups the multivariate ANOVA and independent sample t-test will be used.
Data entry and management Field investigators will enter data collected on pre-programmed tablets that are functioning well. After each day's work, the supervisor will cross check and review all data in the presence of field investigators to ensure that complete and consistent data is finally submitted. The supervisor will flag any aberrant values and consult with the relevant field worker within 24 hours so that gaps will be filled, errors resolved and repeat interviews/visits can be conducted if need be. The submitted data will be accessed by the principal investigator daily for real-time review and monitoring. Once all data have been entered, reviewed and cleaned, final SPSS datasets will be generated and made available to the principal investigator for analysis. As soon as the manuscripts summarizing the study's primary outcomes are published, all datasets will be made available to any one who request it for research purposes.
Informed consent forms will be stored under lock and key.
- Conditions
- Hypertension, Hand Grip Strength, Body Weight, Iron Deficiency, Anaemia, Total Cholesterol
- Being tested
- Oral nutritional supplementation
- Keywords
- Nutritional and health outcomes, Oral Nutritional Supplement, Elderly, Peri urban, Randomized Controlled Trial
- Medical subject headings
- Hypertension, Body Weight, Iron Deficiencies, Anemia, Protein Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral nutritional supplementationDietary supplement
The oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly
| Study group | Role | What they receive |
|---|---|---|
| Oral nutritional supplement | Experimental | Participants will consume daily for 12 weeks in between meals, a 300 ml oral nutritional supplement Receives: Dietary Supplement: Oral nutritional supplementation |
| No treatment or the control group | No intervention | The participants in the no treatment group or control group will not receive any treatment during the 12 weeks except for nutrition education that will be given at certain points to all the participants |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of serum albumin in g/dL; a change in the concentration of serum albumin from baseline to 12 weeks
A phlebotomist will draw 5 ml of venous blood in the morning after a 12 hour overnight fast from each participant for analysis in the laboratory. This will be done at baseline and after 12 weeks. Generally the reference values for serum albumin level is 3.5 g/dL to 5.5 g/dL, however there could be slight differences for the range depending on the laboratory. Analyses will be carried out to ascertain any change in serum albumin levels between baseline and at 12 weeks. Comparisons will be made to ascertain the differences between the serum albumin concentration of the experimental arm and the no intervention arm at baseline and at 12 weeks. Participants with a serum albumin concentration below the reference range will be classified as having low serum albumin concentration.
Measured: Measurement will be taken at baseline (before commencement of intervention) and after 12 weeks of intervention
Body weight measured in kilograms to determine the change in weight at 3 different points of measurements within the 12 weeks of commencement of intervention
The participants will be weighed in light clothing and without shoes. They will be instructed to stand up straight as possible, with heels close together, legs straight as possible, arms at the sides and shoulders relaxed. Body weight will be recorded to the nearest 0.1 kg. Two weight readings will be taken, however a third reading will be taken if the first two readings differ by more than 0.1kilogram. Periodically, the scale will be calibrated for accuracy. Body weight of each participant will be measured at baseline (before the commencement of the intervention), 6 weeks and 12 weeks. Analyses will be done to find out the trend in change in the body weight along the 3 different points of measurement. Comparisons will be made between the experimental group and the no intervention group at each point of measurement
Measured: At baseline, midline (6 weeks) and endline (12 weeks)
Secondary outcomes (5)
Haemoglobin level in g/dl to determine the prevalence of anaemia at baseline and after 12 weeks
A phlebotomist will draw 5 ml of venous blood in the morning after a 12 hour overnight fast from each participant for analysis in the laboratory to measure the concentration of haemoglobin in mg/dL at baseline and after 12 weeks. The World Health Organization reference values for anaemia in elderly men is haemoglobin level below 13g/dL and for elderly women, haemoglobin level below 12g/dL. Analyses will be carried out to ascertain the prevalence of anaemia at baseline and 12 weeks. Comparisons will be made to determine the differences in the prevalence of anaemia between the experimental arm and the no intervention arm.
Measured: Haemoglobin level measured at baseline (before the intervention) and after 12 weeks
Concentration of serum ferritin in µg/l to determine the prevalence of iron deficiency at baseline and at 12 weeks
A phlebotomist will draw 5 ml of venous blood in the morning after a 12 hour overnight fast from each participant for analysis in the laboratory to measure the concentration of serum ferritin in µg/L at baseline and at 12 weeks. The WHO reference values for iron deficiency in apparently healthy elderly persons (60 years and above) is serum ferritin concentration less than 5 µg/L and for those with infections and inflammation, less than 70µg/L . Analyses will be carried out to ascertain the prevalence of iron deficiency at baseline and 12 weeks. Comparisons will be made to know the differences in the prevalence of iron deficiency between the experimental arm and the no intervention arm at baseline and after 12 weeks
Measured: Baseline and after 12 weeks
Total serum cholesterol measured in mg/dL at baseline and at 12 weeks to determine the change in total serum cholesterol
A phlebotomist will draw 5 ml of venous blood after a 12 hour overnight fast to measure the concentration of total serum cholesterol in mg/dl for all participants at baseline before the intervention and after 12 weeks. Generally, a normal total serum cholesterol level for adults is < 200 mg/dL, borderline high is 200 to 239 mg/dL and high is 240 mg/dL and above. Analyses will be done to know the percentage of participants who have normal, borderline high and high total serum cholesterol at baseline and at endline at 12 weeks. Comparison will be made between the experimental arm and the intervention arm to ascertain the differences in the change in their total serum cholesterol
Measured: Baseline and after 12 weeks
Hand grip strength of the dominant arm measured in kilograms to determine the change in handgrip strength at 3 different points of measurements; At baseline, midline (6 weeks) and endline (12 weeks)
Each participant will sit on chair and with the dynamometer in the hand, position his or her dominant arm at the elbow bent at a 90-degree angle and squeeze the dynamometer as hard as possible for 3 seconds and apply a grip force in a smooth motion to avoid jerking. The reading will be taken in kilograms. This will be repeated twice more for a total of three readings. The average of the three readings is the hand grip strength. Analyses will be done to find out the trend in change in the handgrip strength along the 3 different points of measurement (baseline, 6 weeks and at 12 weeks). Comparisons will be made between the experimental group and the no intervention group at each point of measurement.
Measured: At baseline, midline (6 weeks) and endline (12 weeks)
Systolic and diastolic blood pressure measured in mmHg to determine the prevalence of elevated blood pressure at baseline, midline (6 weeks) and endline (12 weeks)
Participants will sit in a rested position and blood pressure will be measured after a 5 minute rest using a digital sphygmomanometer. The mean of two readings to the nearest mmHg will be recorded. A third reading will be taken if the difference in the first two readings is more than 10mmHg. There will be a 2 minute rest in between measurements. The approved definition of high blood pressure by the WHO is a level of systolic blood pressure of 140 mmHg or more or a level of diastolic blood pressure of 90 mmHg or more. Analyses will be done to find out the trend in change in the blood pressure along the 3 different points of measurement (baseline, 6 weeks and at 12 weeks). Comparisons will be made between the experimental group and the no intervention group at each point of measurement.
Measured: At baseline, midline (6 weeks) and endline (12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2025
- Study start24 Nov 2025
- Primary completion1 Apr 2026
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study participants will be randomized to two arms; one arm will be given a plant-based oral nutritional supplement for 12 weeks and the other arm (control) will not be given any treatment. An oral nutritional supplement arm and a no treatment arm.
- Masking
- None (open label)
- Enrolment
- 81 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Ghana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matilda Anim-Fofie, University of Ghana
- Investigators
- Gloria E. Otoo, PhD in Nutrition, Study director, University of GhanaMatilda Steiner-Asiedu, PhD in Nutrition, Study director, University of GhanaJolene Nyako, PhD in Nutrition, Study director, Council for Scientific and Industrial Research-Food Research Institute, Accra-GhanaFiribu K. Saalia, PhD in Food Science, Study director, University of Ghana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06773975
- Sponsor's protocol ID
- ORTONSINTUGDNFSSFPEMATGLSTJOSA
- Status last verified
- Apr 2026
- First submitted
- 21 Nov 2024
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD and all IPD that underlie results in a publication
Publications
Billingham et al. 2013
Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993 Feb;46(2):153-62. doi: 10.1016/0895-4356(93)90053-4.
PubMed 8437031
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 12-week Pilot Randomized Controlled Trial of an Oral Nutritional Supplement in Improving the Nutritional and Health Outcomes of the Elderly in Peri Urban Communities of the La Nkwantanang Madina Municipality in the Greater Accra Region
- ClinicalTrials.gov ID
- NCT06773975
- Acronym / sponsor ID
- ORTONSINTUGDNFSSFPEMATGLSTJOSA
- Conditions
- Hypertension, Hand Grip Strength, Body Weight, Iron Deficiency, Anaemia, Total Cholesterol
- Keywords
- Nutritional and health outcomes, Oral Nutritional Supplement, Elderly, Peri urban, Randomized Controlled Trial
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 81 participants (actual)
- Lead sponsor
- University of GhanaUniversity, hospital or other
- Study start
- 24 Nov 2025 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 14 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
I am conducting this research to find out if a peanut based food that is ready to use would improve the nutritional and health outcomes of the elderly when they consume it daily for 12 weeks. Eligible participants will be assigned randomly to any of these 2 groups.
- To consume the food once a day in between meals in addition to their usual food for 12 weeks (3 months) or
- A control group that will not be given the food. Measurements such as weight, blood pressure and the hand grip strength will be taken at the certain points of the study. A sterile needle will be used to draw about 5 ml of venous blood (from the arm) at the beginning of the study and after 12 weeks. Analyses would be carried out on the blood to know if the food has made an impact on serum albumin, ferritin, haemoglobin and cholesterol. If the findings of the study are favourable, it would provide insights for a larger randomized controlled trial that could establish the efficacy of a locally produced peanut based food for the feeding of the elderly.
Detailed description
Study design A hybrid study comprising of a cross sequential study and a randomized controlled trial.
Study area The study locations are the following five peri urban communities out of the ten peri urban communities in the La Nkwantanang Madina Municipality (LANMA) of the Greater Accra Region in Ghana; Ayi Mensah, Kweiman, Danfa, Adoteiman and Otinibi. These have been conveniently selected because they are a continuous stretch of five communities in the order listed above to reduce the cost of transportation of data collectors and logistics, distribution of the intervention and data collection based on funds available for the project.
Sample size Assumptions: A Cohen's medium effect size of 0.3, a statistical power of 80% at a 5% level of significance, G-power 3.9.1.7 software generated a sample size of 90 participants per treatment group. Accounting for attrition rate + loss to follow up of 10% = 99 participants * 2 treatment groups
= A total sample size of 198 elderly individuals. This has been rounded off to 200 participants. The census to recruit the 200 eligible participants has been completed as of December 13, 2024.
A cross-sectional survey to identify the relationship between usual dietary intake, handgrip strength and blood pressure has been conducted for the 200 participants. Eighty of the participants will be randomly selected as participants for a 12 week randomized control trial.
Assumptions (80 participants): A Cohen's medium effect size of 0.25, a statistical power of 90% at a 5% level of significance, GPower 3.1.9.4 generated a sample size of 36 participants per treatment group. Accounting for attrition rate and a loss to follow up of 10% = 40 participants * 2 treatment groups. A total sample size of 80 elderly individuals.
Data collection for the randomized control trial An interviewer administered questionnaire will be used to obtain the following information at different points of assessments
Baseline data collection Sociodemographic characteristics and medical history such as age, sex, highest level of education, marital status, ethnicity and use of iron supplements, anti-hypertensive drugs and cholesterol lowering drugs will be collected.
Baseline, midline (6 weeks) and endline (12 weeks) A multiple pass quantitative 24-hour dietary recall to obtain information on dietary intake. Household measures and food models will be used to estimate portion sizes. The Physical Activity Scale for the Elderly (PASE) by Washburn et al. (1993) will be used to measure level of physical activity. Body weight, hand grip strength, systolic and diastolic blood pressure will be measured.
Weekly All participants will receive nutrition education at baseline and weekly thereafter. Information on adherence will be collected by evidence of pouches of previous week's ration to calculate percentage of quantity consumed. The 24-hour dietary recall will also be used to track adherence. Information on morbidity on the use of oral nutritional supplements will be collected using the questionnaire for gastrointestinal problems adapted from Pereira et al. (2014).
Baseline and 12 weeks A qualified phlebotomist will take a 5ml venous blood for analyses of the following: serum albumin, serum ferritin, serum cholesterol and haemoglobin
The intervention A 7-day ration of the oral nutritional supplement will be distributed to the intervention arm once a week. A day's serving of 330 ml is to be consumed in between meals. After endline data collection, the control arm will be given a ration of the oral nutritional supplement that will be enough for one month.
Statistical analyses
- To investigate the effect of sociodemographic characteristics, dietary intake and level of physical activity on the outcome measures, binary logistic regression for categorical variables, multinomial or ordinal logistics regression for multiple variables and linear regression for continuous variables
- To determine the efficacy of the oral nutritional supplement on outcome measures within the same treatment arm, repeated measures ANOVA and paired-sample t-test will be used
- To determine the differences in outcomes between the treatment groups the multivariate ANOVA and independent sample t-test will be used.
Data entry and management Field investigators will enter data collected on pre-programmed tablets that are functioning well. After each day's work, the supervisor will cross check and review all data in the presence of field investigators to ensure that complete and consistent data is finally submitted. The supervisor will flag any aberrant values and consult with the relevant field worker within 24 hours so that gaps will be filled, errors resolved and repeat interviews/visits can be conducted if need be. The submitted data will be accessed by the principal investigator daily for real-time review and monitoring. Once all data have been entered, reviewed and cleaned, final SPSS datasets will be generated and made available to the principal investigator for analysis. As soon as the manuscripts summarizing the study's primary outcomes are published, all datasets will be made available to any one who request it for research purposes.
Informed consent forms will be stored under lock and key.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study participants will be randomized to two arms; one arm will be given a plant-based oral nutritional supplement for 12 weeks and the other arm (control) will not be given any treatment. An oral nutritional supplement arm and a no treatment arm.
| Arm | Type | Receives |
|---|---|---|
| Oral nutritional supplement | Experimental | Dietary Supplement: Oral nutritional supplementationParticipants will consume daily for 12 weeks in between meals, a 300 ml oral nutritional supplement |
| No treatment or the control group | No intervention | –The participants in the no treatment group or control group will not receive any treatment during the 12 weeks except for nutrition education that will be given at certain points to all the participants |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Elderly individuals aged 60 years and above
- Consent to participate
Key exclusion criteria (11 listed)
- Peanut allergy
- Millet allergy
- Sesame seeds allergy
- The use of oral nutritional supplement
- Sickle cell disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral nutritional supplementationThe oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly | Dietary supplement | Oral nutritional supplement |
Primary outcome
Concentration of serum albumin in g/dL; a change in the concentration of serum albumin from baseline to 12 weeks
Time frame: Measurement will be taken at baseline (before commencement of intervention) and after 12 weeks of intervention
A phlebotomist will draw 5 ml of venous blood in the morning after a 12 hour overnight fast from each participant for analysis in the laboratory. This will be done at baseline and after 12 weeks. Generally the reference values for serum albumin level is 3.5 g/dL to 5.5 g/dL, however there could be slight differences for the range depending on the laboratory. Analyses will be carried out to ascertain any change in serum albumin levels between baseline and at 12 weeks. Comparisons will be made to ascertain the differences between the serum albumin concentration of the experimental arm and the no intervention arm at baseline and at 12 weeks. Participants with a serum albumin concentration below the reference range will be classified as having low serum albumin concentration.
Body weight measured in kilograms to determine the change in weight at 3 different points of measurements within the 12 weeks of commencement of intervention
Time frame: At baseline, midline (6 weeks) and endline (12 weeks)
The participants will be weighed in light clothing and without shoes. They will be instructed to stand up straight as possible, with heels close together, legs straight as possible, arms at the sides and shoulders relaxed. Body weight will be recorded to the nearest 0.1 kg. Two weight readings will be taken, however a third reading will be taken if the first two readings differ by more than 0.1kilogram. Periodically, the scale will be calibrated for accuracy. Body weight of each participant will be measured at baseline (before the commencement of the intervention), 6 weeks and 12 weeks. Analyses will be done to find out the trend in change in the body weight along the 3 different points of measurement. Comparisons will be made between the experimental group and the no intervention group at each point of measurement
5 secondary outcomes
Haemoglobin level in g/dl to determine the prevalence of anaemia at baseline and after 12 weeks
Time frame: Haemoglobin level measured at baseline (before the intervention) and after 12 weeks
Concentration of serum ferritin in µg/l to determine the prevalence of iron deficiency at baseline and at 12 weeks
Time frame: Baseline and after 12 weeks
Total serum cholesterol measured in mg/dL at baseline and at 12 weeks to determine the change in total serum cholesterol
Time frame: Baseline and after 12 weeks
Hand grip strength of the dominant arm measured in kilograms to determine the change in handgrip strength at 3 different points of measurements; At baseline, midline (6 weeks) and endline (12 weeks)
Time frame: At baseline, midline (6 weeks) and endline (12 weeks)
Systolic and diastolic blood pressure measured in mmHg to determine the prevalence of elevated blood pressure at baseline, midline (6 weeks) and endline (12 weeks)
Time frame: At baseline, midline (6 weeks) and endline (12 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
- BackgroundBillingham et al. 2013
- Background: PubMed 8437031Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993 Feb;46(2):153-62. doi: 10.1016/0895-4356(93)90053-4.
- Individual participant dataSharing planned: Yes. All collected IPD and all IPD that underlie results in a publication
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gloria E. Otoo, PhD in Nutrition study director
University of Ghana
Matilda Steiner-Asiedu, PhD in Nutrition study director
University of Ghana
Jolene Nyako, PhD in Nutrition study director
Council for Scientific and Industrial Research-Food Research Institute, Accra-Ghana
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Oral nutritional supplementation in people with Hypertension and Hand Grip Strength, run by University of Ghana at 1 site in Ghana.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ghana. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of serum albumin in g/dL; a change in the concentration of serum albumin from baseline to 12 weeks (time frame: Measurement will be taken at baseline (before commencement of intervention) and after 12 weeks of intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06773975, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.